Cuprina characterizes itself as dedicated to chronic wound management, infertility-related products, cosmeceuticals and medical waste recycling, with activities spanning medical devices, biotherapeutic modalities like maggot and leech therapies, IVF media production, and collagen-based research. The company went public via IPO on April 10, 2025, raising $12 million at $4 per share on NASDAQ, though it faces operational and regulatory challenges as a micro-cap biotech.
Cyborg Score Rationale
The company had trailing twelve months revenue of only $39K and net income of -$3.6M as of recent reporting. CUPR has declined 90.16% over the past year, with a stock price collapse from $9.50 (August 2025) to $0.28 (March 2026). The company received a Nasdaq minimum bid price deficiency notification in November 2025 and is evaluating options to regain compliance.
Top Insights
As of April 9, 2026, the company employed only 14 people, indicating an extremely early-stage operation
Through subsidiary Cuprina MENA Co. Ltd, the company secured exclusive rights to sell medicinal leeches across Gulf Cooperation Council countries for treating venous congestion and post-surgical healing
The company disclosed a Nasdaq notification letter regarding minimum bid price deficiency but stated this does not result in immediate delisting
Business model depends on commercializing bio-therapies (maggot therapy, leech therapy, collagen dressings) in chronic wound markets with unproven commercial traction
Named Competitors
Advanced Wound Care — Leading global wound care manufacturer
Medline Wound Care — Large medical device and wound care supplier
Bio-D Technologies — Alternative biotherapy wound debridement solutions
Recent Developments
(April 2025) IPO on NASDAQ at $4/share, raising $12 million
(May 2025) Closed underwriter's over-allotment option in IPO
(June 2025) Completed lab capable of supplying MEDIFLY chronic wound therapy across MENA region and secured exclusive license to market medicinal leeches in GCC countries
(November 2025) Received Nasdaq notification letter regarding minimum bid price deficiency under listing rules
Open the full interactive Cuprina Holdings (Cayman) Limited report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.